EGFR and non-small cell lung carcinoma: Although first‐line osimertinib plus chemotherapy is not cost‐effective in the whole EGFR‐mutated (Ex19del or L858R) advanced NSCLC population, our subgroup analyses have revealed heterogeneities among populations.